NCT05968430Phase 3Active not recruiting

Open-Label Extension (OLE) Study to Assess Safety, Efficacy, and Tolerability of Lorundrostat in Subjects With Hypertension

Study sponsor: Mineralys Therapeutics Inc. · MLYS

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2025-12-30Actual
Enrollment · participants1076Actual
Source updated2026-11-04Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 4 fields changed

Participant count type changed

Before: Estimated. After: Actual.

Enrollment · participant count changed

Before: 1400 participants (planned). After: 1076 participants (actual).

Completion date type changed

Before: Estimated. After: Actual.

Primary completion date changed

Before: Dec 2025. After: 30 Dec 2025.

Check registry source

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview